Delayed sentinel lymph node biopsy with the Magtrace® lymphatic tracer

The long injection window of Magtrace® means you can now confirm if your patients DCIS is invasive before performing surgery in the axilla - as demonstrated in the 2019 SentiNOT study(Karakatsanis et al, 2019).

It is uncommon for DCIS, the earliest form of breast cancer, to be invasive. For many women in this position, axillary staging may be unecessary. It increases the surgical procedure risk and can potentially result in morbidity issues, such as lymphedema.

Only 20% of patients with high risk DCIS are upgraded to an invasive breast cancer diagnosis after surgery and pathologic assessment of their cancer. This means that 4 out of 5 patients who undergo DCIS treatment do not need the SLNB procedure that has now become common practice.

In total, this equates to around 50,000 women undergoing an unnecessary surgical procedure to stage a non-invasive cancer every year.

The Magtrace® lymphatic tracer is proven to eliminate the need for SLNB where it is not required, helping to reduce patient side effects by offering them a better standard of care.

Magtrace® is optimized to allow hospitals the flexibility to inject and mark the patients sentinel lymph nodes weeks ahead of surgery.

This means you can now wait for your DCIS pathologic staging results before deciding if a SLNB is required, potentially sparing your patients unnecessary surgery.

Research from the SentiNOT study, conducted by Dr. Andreas Karakatsanis and his team at the University of Uppsala in Sweden, helped to establish the delayed SLNB technique in 2019.

Since the release of this paper, numerous institutes and physicians have continued to research and practice the technique around the world.

- 78.3% avoided SLNB

- 100% success rate

- 24.5% lowered costs

Magtrace® can be administered in the OR after anesthesia to eliminate patient pain. If injected days before surgery, Magtrace® has been noted to be less painful than radioactive isotope.

The 60nm particles in Magtrace® are optimized to be mechanically filtered by the sentinel lymph nodes and not pass to higher-echelon nodes, regardless of when it is injected.

Magtrace® has a detection rate of up to 99.3%, finds an average of 2.4 nodes per patient and is non-inferior to radioisotope and blue dye. Not only that, but it also discolors the node, offering additional visual backup.

Give your patients a better standard of breast cancer surgery without the need for wires and radioactivity.

→ Set up a no cost, no commitment evaluation today.